GILEAD SCIENCES, INC. Other Revenue, Net (Deprecated 2018-01-31)
GILEAD SCIENCES, INC. (GILD) reported Other Revenue, Net (Deprecated 2018-01-31) of $87.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-05-09
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $87.00M, a 32.03% decline year-over-year.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $112.00M, a 7.69% increase year-over-year.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $110.00M, a 15.79% increase year-over-year.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $95.00M, a 24.00% decline year-over-year.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $445.00M, a 1.83% increase from fiscal 2016.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $437.00M, a 10.45% decline from fiscal 2015.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $488.00M, a 17.31% increase from fiscal 2014.
- GILEAD SCIENCES, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $416.00M, a 2841.18% increase from fiscal 2013.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $87.00M 10-Q · filed 2018-05-09 | $199.00M derived: sum of 2 quarters · filed 2018-05-09 | $309.00M derived: sum of 3 quarters · filed 2018-05-09 | $404.00M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $112.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $222.00M derived: sum of 2 quarters · filed 2018-02-27 | $317.00M derived: sum of 3 quarters · filed 2018-02-27 | $445.00M 10-K · filed 2018-02-27 |
| 2017-09-30 | $110.00M 10-Q · filed 2017-11-07 | $205.00M derived: sum of 2 quarters · filed 2017-11-07 | $333.00M 10-Q · filed 2017-11-07 | $437.00M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $95.00M 10-Q · filed 2017-08-07 | $223.00M 10-Q · filed 2017-08-07 | $327.00M derived: sum of 3 quarters · filed 2018-05-09 | $422.00M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $128.00M 10-Q · filed 2018-05-09 | $232.00M derived: sum of 2 quarters · filed 2018-05-09 | $327.00M derived: sum of 3 quarters · filed 2018-05-09 | $452.00M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $104.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $199.00M derived: sum of 2 quarters · filed 2018-02-27 | $324.00M derived: sum of 3 quarters · filed 2018-02-27 | $437.00M 10-K · filed 2018-02-27 |
| 2016-09-30 | $95.00M 10-Q · filed 2017-11-07 | $220.00M derived: sum of 2 quarters · filed 2017-11-07 | $333.00M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $125.00M 10-Q · filed 2017-08-07 | $238.00M 10-Q · filed 2017-08-07 | ||
| 2015-12-31 | $488.00M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $416.00M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $6.89M derived: sum of 2 quarters · filed 2014-02-25 | $10.48M derived: sum of 3 quarters · filed 2014-02-25 | $14.14M 10-K · filed 2014-02-25 |
| 2013-09-30 | $3.40M 10-Q · filed 2013-10-31 | $7.00M derived: sum of 2 quarters · filed 2013-10-31 | $10.66M 10-Q · filed 2013-10-31 | $13.73M derived: sum of 4 quarters · filed 2014-02-25 |
| 2013-06-30 | $3.60M 10-Q · filed 2013-08-01 | $7.25M 10-Q · filed 2013-08-01 | $10.33M derived: sum of 3 quarters · filed 2014-02-25 | $15.04M derived: sum of 4 quarters · filed 2014-02-25 |
| 2013-03-31 | $3.66M 10-Q · filed 2013-05-08 | $6.74M derived: sum of 2 quarters · filed 2014-02-25 | $11.44M derived: sum of 3 quarters · filed 2014-02-25 | $14.28M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $7.78M derived: sum of 2 quarters · filed 2014-02-25 | $10.62M derived: sum of 3 quarters · filed 2014-02-25 | $13.62M 10-K · filed 2014-02-25 |
| 2012-09-30 | $4.70M 10-Q · filed 2013-10-31 | $7.54M derived: sum of 2 quarters · filed 2013-10-31 | $10.55M 10-Q · filed 2013-10-31 | $13.38M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $2.84M 10-Q · filed 2013-08-01 | $5.84M 10-Q · filed 2013-08-01 | $8.67M derived: sum of 3 quarters · filed 2014-02-25 | $12.85M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $3.00M 10-Q · filed 2013-05-08 | $5.83M derived: sum of 2 quarters · filed 2014-02-25 | $10.01M derived: sum of 3 quarters · filed 2014-02-25 | $13.35M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $7.00M derived: sum of 2 quarters · filed 2014-02-25 | $10.35M derived: sum of 3 quarters · filed 2014-02-25 | $14.20M 10-K · filed 2014-02-25 |
| 2011-09-30 | $4.17M 10-Q · filed 2012-11-06 | $7.52M derived: sum of 2 quarters · filed 2012-11-06 | $11.37M 10-Q · filed 2012-11-06 | $14.68M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $3.34M 10-Q · filed 2012-08-01 | $7.20M 10-Q · filed 2012-08-01 | $10.50M derived: sum of 3 quarters · filed 2013-02-27 | $13.24M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $3.85M 10-Q · filed 2012-05-04 | $7.16M derived: sum of 2 quarters · filed 2013-02-27 | $9.90M derived: sum of 3 quarters · filed 2013-02-27 | $13.27M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $6.05M derived: sum of 2 quarters · filed 2013-02-27 | $9.42M derived: sum of 3 quarters · filed 2013-02-27 | $13.53M 10-K · filed 2013-02-27 |
| 2010-09-30 | $2.74M 10-Q · filed 2011-11-04 | $6.11M derived: sum of 2 quarters · filed 2011-11-04 | $10.22M 10-Q · filed 2011-11-04 | $15.45M derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-06-30 | $3.37M 10-Q · filed 2011-08-05 | $7.48M 10-Q · filed 2011-08-05 | $12.71M derived: sum of 3 quarters · filed 2012-02-23 | $23.02M derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-03-31 | $4.11M 10-Q · filed 2011-05-09 | $9.34M derived: sum of 2 quarters · filed 2012-02-23 | $19.64M derived: sum of 3 quarters · filed 2012-02-23 | $24.52M derived: sum of 4 quarters · filed 2012-02-23 |
| 2009-12-31 | $5.23M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $15.53M derived: sum of 2 quarters · filed 2012-02-23 | $20.42M derived: sum of 3 quarters · filed 2012-02-23 | $50.25M 10-K · filed 2012-02-23 |
| 2009-09-30 | $10.30M 10-Q · filed 2010-11-08 | $15.18M derived: sum of 2 quarters · filed 2010-11-08 | $45.02M 10-Q · filed 2010-11-08 | $52.49M derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-06-30 | $4.88M 10-Q · filed 2010-08-09 | $34.72M 10-Q · filed 2010-08-09 | $42.19M derived: sum of 3 quarters · filed 2011-02-28 | $49.80M derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-03-31 | $29.84M 10-Q · filed 2010-05-10 | $37.31M derived: sum of 2 quarters · filed 2011-02-28 | $44.92M derived: sum of 3 quarters · filed 2011-02-28 | $55.22M derived: sum of 4 quarters · filed 2011-02-28 |
| 2008-12-31 | $7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $15.08M derived: sum of 2 quarters · filed 2011-02-28 | $25.38M derived: sum of 3 quarters · filed 2011-02-28 | $32.77M 10-K · filed 2011-02-28 |
| 2008-09-30 | $7.61M 10-Q · filed 2009-11-05 | $17.91M derived: sum of 2 quarters · filed 2009-11-05 | $25.30M 10-Q · filed 2009-11-05 | |
| 2008-06-30 | $10.30M 10-Q · filed 2009-08-05 | $17.70M 10-Q · filed 2009-08-05 | ||
| 2007-12-31 | $28.78M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |